Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib with melphalan and prednisone in advanced multiple myeloma
NCT01116128Phase 2Terminated
- Sponsor
- Fondazione EMN Italy
- Start
- Feb 2008
- Primary completion
- May 2011
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dasatinib in multiple myeloma (MM), sponsored by Fondazione EMN Italy. Started Feb 2008; status: terminated.
02
Drugs
dasatinib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01116128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01116128.